Doxorubicin Market Research Report Information by Application (liver cancer, lung cancer), By Distribution Channel (hospital pharmacy, retail pharmacy) - Forecast Till 2032

Doxorubicin Market Overview

Doxorubicin Market Size was valued at USD 0.98 Billion in 2023. The Doxorubicin industry is projected to grow from USD 1.06 Billion in 2024 to USD 1.90 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.6% during the forecast period (2024 - 2032). Doxorubicin is the generic drug used to treat cancer chemotherapy drugs Adriamycin and Rubex. It is an anthracycline antibiotic and belongs to the anti-cancer group of anti-cancer. 

The medications are antineoplastic and are made from the natural product produced by the bacterium Streptomyces peucetius var. caesius. Doctors use this for the treatment of different types of cancer. The cancers that can be treated through this are breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms' tumour, Hodgkin's, and non-Hodgkin's lymphomas. Less commonly, it is also used to treat squamous cell carcinomas of the head and neck. Vagina and cervix, multiple refractory myeloma, and neuroblastoma. Doxorubicin slows down the proliferation rate of cancerous cells by intercalating between the base pairs in the DNA helix. And this can prevent DNA replication and inhibit protein synthesis. The market is facing good growth due to several reasons. One of the major reasons is the rise in cancer patients worldwide, which is the main cause of death. The lifestyle that people are adopting, which causes more cancer cells in the body, is another cause of the growth.

In January 2023, BiotechPharma Inc., a major drug manufacturer, announced that it had successfully completed a Phase III clinical trial for a new formulation of Doxorubicin with increased efficacy and fewer side effects. By the end of this year, the company expects to receive approval for the novel formulation.

In April 2023, MedLife Solutions, which is a health tech organization, disclosed an invention on a drug release mechanism that is capable of breaking Doxorubicin at any moment it is desired. It will work together with Drug-making firms so as to have this in their Drugs for Doxorubicin, resulting in improved therapy outcomes and reduced damage to normal tissue by Doxorubicin.

In June 2023, GenoBioPharma, a bio-pharmaceutical start-up, announced the study conducted in relation to combining Doxorubicin with targeted immunotherapies, having resulted in some achievements. According to preclinical studies, this combination significantly boosted the immune response against cancer cells and maximized the cytotoxic effect caused by Doxorubicin. In addition, GenoBioPharma would initiate clinical trials to evaluate its therapeutic benefits and safety profile among cancer patients when administered concomitantly with conventional therapies such as chemotherapy.

Doxorubicin Market Segment Insights

The doxorubicin market has been segmented on the basis of application, and distribution channel.

Doxorubicin Application Insights

The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.

Doxorubicin Distrubution Channel Insights

The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.

Doxorubicin Regional Insights

The doxorubicin market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The doxorubicin market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are expected to dominate the doxorubicin market owing to the growing pool of cancer patients associated with increasing elderly population, strong presence of major manufacturers in the region, and adoption of advanced healthcare facilities coupled with increased awareness about cancer treatment in general population. In 2016, according to the National Cancer Institute in United states approximately USD 147.3 billion were spend for cancer care and around 15.5 million new cases of cancer were registered.

The European market is expected to be the second-largest doxorubicin market. The market growth in this region can be attributed to the growing prevalence of cancer along with rising healthcare expenditure is expected to drive the growth of the market. In 2016, according to European commission, the European nations invested 16.2% of its total expenditure on healthcare.

Asia-Pacific is expected to be the fastest-growing doxorubicin market during the forecast period owing to the continuously increasing investment in healthcare, increasing geriatric population in the region, and increasing opportunities for various manufacturers. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), 12.4% of the total Asian population is 60 or above 60-year-old and by 2050 one third of the population will cross 60 year.

The market in the Middle East & Africa is expected to account for the smallest share of the doxorubicin market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Market of Doxorubicin, by Application

• Liver cancer


• Gastric cancer


• Breast cancer


• Bone sarcoma


• Prostate cancer


• Stomach Cancer


• Ovarian cancer


• Leukemia


• others

Market of Doxorubicin, by Distribution Channel

• Hospital pharmacy


• Retail pharmacy


• Others

Market of Doxorubicin, by Region

• Americas




• North America




• US


• Canada




• South America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Company Profiles

• Pfizer, Inc


• Janssen Pharmaceuticals


• Accord Healthcare


• Novartis AG


• Sun Pharmaceutical Industries Ltd.


• Sandoz


• Reddy’s Laboratories Ltd.


• Teva Pharmaceuticals


• GLENMARK PHARMACEUTICALS LTD.

Recent Development

April 2022

The research group of the University of Manitoba in Canada found that vitamin C improved markers of heart health and survival in rats given doxorubicin, mainly by reducing oxidative stress and inflammation. The new study assessed whether vitamin C could similarly help prevent doxorubicin's adverse effects on skeletal muscle.

The research found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte apoptosis and mitochondrial dysfunction induced by Dox treatment.

 May 2022

A team of researchers from the National University of Singapore (NUS) is best for novel magnetic therapy. This is delivered using the OncoFTX System, which serves as an effective companion therapy to chemotherapy to enhance treatment outcomes for breast cancer.

Intended Audience

• Doxorubicin manufacturing suppliers and companies


• Healthcare providers


• Research institutes and academic centers


• Contract manufacturing organizations (CMOs)


• Market research and consulting